Compare KFRC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | ENTA |
|---|---|---|
| Founded | 1962 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.6M | 407.5M |
| IPO Year | 1995 | 2013 |
| Metric | KFRC | ENTA |
|---|---|---|
| Price | $29.58 | $14.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $34.75 | $20.40 |
| AVG Volume (30 Days) | 251.8K | ★ 290.2K |
| Earning Date | 11-03-2025 | 11-17-2025 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $1,340,771,000.00 | $65,324,000.00 |
| Revenue This Year | N/A | $0.99 |
| Revenue Next Year | N/A | $0.19 |
| P/E Ratio | $13.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.49 | $4.09 |
| 52 Week High | $61.81 | $15.34 |
| Indicator | KFRC | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 69.86 |
| Support Level | $29.00 | $11.89 |
| Resistance Level | $30.42 | $14.52 |
| Average True Range (ATR) | 1.06 | 0.86 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 71.58 | 84.75 |
Kforce Inc is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. The company operates two business segments: 1) In technology segment it provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. 2) In FA segment company offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting business and cost analysis; and taxation and treasury. The majority of revenue is earned through the technology segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.